Selected Publications from 2000 to Present:
Han BH, D'Costa A, Back SA, Parsadanian M, Patel S, Shah AR, Gidday JM, Srinivasan A, Deshmukh M, Holtzman DM. BDNF blocks caspase-3 activation in neonatal hypoxia-ischemia. Neurobiology of Disease 2000;7:38-53.
Holtzman DM, Bales KR, Tenkova T, Fagan AM, Parsadanian M, Sartorius LJ, Mackey B, Olney J, McKeel D, Wozniak D, Paul SM (2000). Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 2000;97:2892-2897.
Holtzman DM, Fagan AM, Mackey B, Tenkova T, Sartorius L, Paul SM, Bales K, Ashe KH, Irizzary MC, Hyman BT. (2000) ApoE facilitates neuritic and cerebrovascular plaque formation in the APPsw mouse model of Alzheimer's disease. Ann Neurol 47:739-747.
Fagan AM, Younkin LH, Morris JC, Cole TG, Younkin SG, Holtzman DM. (2000) Differences in Ab 40/42 ratio associated with CSF lipoproteins as a function of apoE genotype. Ann. Neurol. 48:201-210.
Han BH, DeMattos RB, Dugan LL, Kim-Han JS, Brendza R, Fryer JD, Kierson M, Cirrito J, Quick K, Harmony JAK, Aronow BJ, Holtzman DM. (2001) Clusterin contributes to caspase-3 independent brain injury following neonatal hypoxia-ischemia. Nature Med. 7:338-343.
DeMattos RB, Bales KR, Cummins DJ, Dodart J-C, Paul SM, Holtzman DM. (2001) Peripheral anti-Ab antibody alters CNS and plasma Ab clearance and decreases brain Ab burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 98: 8850-8855:10.1073/pnas.151261398.
DeMattos RB, Bales KR, Cummins DJ, Paul SM, Holtzman DM. (2002) Brain to plasma amyloid-b efflux: A measure of brain amyloid burden in a mouse model of Alzheimer's disease. Science 295:2264-2267.
DeMattos RB, Bales KR, Kierson ME, O'Dell MA, Foss EM, Paul SM, Holtzman DM. (2002) Plaque associated disruption of CSF and plasma Ab equilibrium in a mouse model of Alzheimer's disease. J. Neurochem. 81:229-236.
Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. (2002) Human and murine apoE markedly influence Ab metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol. Dis. 9:305-318.
Dodart JC, Bales KR, Gannon KS, Greene SJ, DeMattos RB, Mathis C, DeLong CA, Wu S, Wu X, Holtzman DM, Paul SM. (2002) Immunization reverses memory deficits without reducing Ab burden in Alzheimer's disease model. Nature Neurosci. 5:452-457.
Han BH, Xu D, Choi J, Han Y, Xanthoudakis S, Roy S, Tam J, Vaillancourt J, Colucci J, Siman R, Giroux A, Robertson GS, Zamboni R, Nicholson DW, Holtzman DM. (2002) Selective, reversible caspase-3 inhibitor is neuroprotective and reveals distinct pathways of cell death following neonatal hypoxic-ischemic brain injury. J. Biol. Chem. 277:30128-30136.
Arvin KL, Han BH, Du Y, Lin S, Paul SM, Holtzman DM. (2002) Minocycline markedly protects the neonatal brain against hypoxic-ischemic injury. Ann. Neurol. 52:54-61.
DeMattos RB, O'Dell MA, Parsadanian M, Taylor JW, Harmony JAK, Bales KR, Paul SM, Aronow BJ, Holtzman DM. (2002) Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. USA 99:10843-10848. (10.1073/pnas.162228299)
Hartman RE, Laurer H, Longhi L, Bales KR, Paul SM, McIntosh TK, Holtzman DM. (2002) APOE4 influences amyloid deposition but not cell loss after traumatic brain injury in a mouse model of Alzheimer's disease. J. Neurosci. 22:10083-10087.
Brendza RP, O'Brien C, Simmons K, McKeel DW, Bales KR, Paul SM, Olney JW, Sanes JR,, Holtzman DM. (2003) PDAPP;YFP double transgenic mice: A tool to study amyloid-b associated changes in axonal, dendritic, and synaptic structure. J. Comp. Neurol. 456:375-383.
Fryer JD, Taylor JW, DeMattos RB, Bales KR, Paul SM, Parsadanian M, Holtzman DM (2003) Apolipoprotein E markedly facilitates age-dependent cerebral amyloid angiopathy and spontaneous hemorrhage in APP transgenic mice. Journal of Neuroscience 23: 7889-7896.
Cirrito JR, May PC, O'Dell MA, Taylor JW, Parsadanian M, Cramer JW, Audia JE, Nissen JS, Bales KR, Paul SM, DeMattos RB, Holtzman DM. (2003) In vivo assessment of brain interstitial fluid with microdialysis reveals plaque-associated changes in amyloid-b metabolism and half-life. Journal of Neuroscience 23:8844-8853.
DeMattos R, Cirrito J, O'Dell M, Taylor J, Harmony J, Aronow B, Bales K, Paul S, Holtzman DM. (2004) ApoE and clusterin cooperative suppress Ab levels and deposition: Evidence that ApoE regulates extracellular Ab metabolism in vivo. Neuron 41:193-202.
Wahrle, SE, Jiang H, Parsadanian M, Legleiter J, Han X, Fryer JD, Kowalewski T and Holtzman, DM (2004) ABCA1 is required for normal CNS apoE levels and for lipidation of astrocyte-secreted apoE. Journal of Biological Chemistry 279(39):40987-20993.
Brendza RP, Bacskai BJ, Cirrito JR, Simmons KA, Skoch JM, Klunk WE, Mathis CA, Bales KR, Paul SM, Hyman BT, Holtzman DM. Anti- Ab antibody treatment promotes the rapid recovery of amyloid-associated neuritic dystrophy in PDAPP transgenic mice. J Clin Invest. 2005; 115: 428-433.
Morikawa M, Fryer JD, Sullivan PM, Christopher EA, Wahrle SE, DeMattos RB, O'Dell MA, Fagan AM, Lashuel HA, Walz T, Asai K, Holtzman DM. (2005) Production and characterization of astrocyte-derived human apolipoprotein E isoforms from immortalized astrocytes and their interactions with amyloid-b. Neurobiology of Disease 19:66-76.
Fryer JD, Simmons K, Parsadanian M, Bales KR, Paul SM, Sullivan PM, Holtzman DM. (2005) Human apolipoprotein E4 alters the amyloid-b 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. Journal of Neuroscience 25:2803-2810.
Loren DJ, Seeram NP, Schulman RN, Holtzman DM. (2005) Maternal Dietary Supplementation with Pomegranate Juice Is Neuroprotective in an Animal Model of Neonatal Hypoxic-Ischemic Brain Injury. Pediatric Research 57:858-864.
Hartman RE, Izumi Y, Bales KR, Paul SM, Wozniak DF, Holtzman DM. (2005)
Treatment with an amyloid-b antibody ameliorates plaque load, learning deficits, and hippocampal long-term potentiation in a mouse model of Alzheimer's disease. Journal of Neuroscience 25: 6213 - 6220.
Hu Y, Townsend RR, Fagan AM, Holtzman DM. (2005) Comparative proteomic analysis of intra- and inter-individual variation in human cerebrospinal fluid. Molecular and Cellular Proteomics 4(12):2000-9.
Wahrle SE, Jiang H, Parsadanian M, Hartman RE, Bales KR, Paul SM, Holtzman DM (2005) Deletion of Abca1 increases Ab deposition in the PDAPP transgenic mouse model of Alzheimer's disease Journal of Biological Chemistry 280(52):43236-43242.
Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM. (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-b deposition in an Alzheimer's disease mouse model. J. Clin. Invest. 115: 3285 - 3290.
Cirrito JR, Yamada KA, Finn MB, Sloviter RS, Bales KR, May PC, Schoepp DD, Paul SM, Mennerick S, Holtzman DM. (2005) Synaptic activity regulates interstitial fluid amyloid-b levels in vivo. Neuron 48(6):913-922.
Brody D, Holtzman DM. (2006) Morris water maze search strategy analysis in PDAPP mice before and after experimental traumatic brain injury.Exp Neurol. 197(2):330-40.
West T, Atzeva M, Holtzman DM (2006) Caspase-3 deficiency during development increases vulnerability to hypoxic-ischemic injury through caspase-3-independent pathways. Neurobiol Dis. 22(3):523-37.
Fagan AM, Mintun MA, Mach RH, Lee SY, Dence CS, Shah AR, LaRossa GN, Spinner ML, Klunk WE, Mathis CA, DeKosky ST, Morris JC, Holtzman DM. Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
Ann Neurol. 2006 Mar;59(3):512-9. PMID: 16372280 [PubMed - indexed for MEDLINE]
Bateman RJ, Munsell LY, Morris JC, Swarm R, Yarasheski KE, Holtzman DM. Human amyloid-beta synthesis and clearance rates as measured in cerebrospinal fluid in vivo. Nat Med. 2006 Jul;12(7):856-61. Epub 2006 Jun 25.
Hartman RE, Shah A, Fagan AM, Schwetye KE, Parsadanian M, Schulman RN, Finn MB, Holtzman DM.Pomegranate juice decreases amyloid load and improves behavior in a mouse model of Alzheimer's disease.Neurobiol Dis. 2006 Dec;24(3):506-15. Epub 2006 Sep 28.
Fagan AM, Roe CM, Xiong C, Mintun MA, Morris JC, Holtzman DM. Cerebrospinal fluid tau/beta-amyloid(42) ratio as a prediction of cognitive decline in nondemented older adults. Arch Neurol. 2007 Mar;64(3):343-9. Epub 2007 Jan 8.
Bateman RJ, Wen G, Morris JC, Holtzman DM. Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.
Neurology. 2007 Feb 27;68(9):666-9. PMID: 17325273 [PubMed - indexed for MEDLINE]
Wahrle SE, Shah AR, Fagan AM, Smemo S, Kauwe JS, Grupe A, Hinrichs A, Mayo K, Jiang H, Thal LJ, Goate AM, Holtzman DM. Apolipoprotein E levels in cerebrospinal fluid and the effects of ABCA1 polymorphisms. Mol Neurodegener. 2007 Apr 12;2:7. PMID: 17430597
West T, Atzeva M, Holtzman DM. Pomegranate polyphenols and resveratrol protect the neonatal brain against hypoxic-ischemic injury. Dev Neurosci. 2007;29(4-5):363-72.
Kang JE, Cirrito JR, Dong H, Csernansky JG, Holtzman DM. Acute stress increases interstitial fluid amyloid-beta via corticotropin-releasing factor and neuronal activity.Proc Natl Acad Sci U S A. 2007 Jun 19;104(25):10673-8. Epub 2007 Jun 5
Wahrle SE, Jiang H, Parsadanian M, Kim J, Li A, Knoten A, Jain S, Hirsch-Reinshagen V, Wellington CL, Bales KR, Paul SM, Holtzman DM. Overexpression of ABCA1 reduces amyloid deposition in the PDAPP mouse model of Alzheimer disease. J Clin Invest. 2008 Jan 17; [Epub ahead of print], 118(2):671-682.
Cirrito JR, Kang J-E, LeeJ, Stewart FR,Verges D, Silverio LM BuG, MennerickS, Holtzman DM. Endocytosis is required for synaptic activity-dependent release of amyloid-b in vivo. Neuron 2008 58:42-51.
Holtzman DM. (2008) Alzheimer's disease: Moving towards a vaccine. Nature 24;454(7203):418-20. PMID: 18650906
Brody DL, Holtzman DM. Active and Passive Immunotherapy for Neurodegenerative Disorders. Annu Rev Neurosci. 2008 Mar 19. [Epub ahead of print] PMID: 18352830
Brody DL, Magnoni S, Schwetye KE, Spinner M, Esparza TJ, Stocchetti N, Zipfel GJ, Holtzman DM. (2008) Amyloid-β Dynamics Correlate with Neurological Status in the Injured Human Brain Science 321:1221 - 1224. PMID: 18755980
Koenigsknecht-Talboo J, Meyer-Luehmann M, Parsadanian M, Garcia-Alloza M, Finn MB, Hyman BT, Bacskai BJ, Holtzman DM. 2008 Rapid microglial response around amyloid pathology after systemic anti-Abeta antibody administration in PDAPP mice. J Neurosci. 28(52):14156-64. PMID: 19109498
Bateman RJ, Siemers ER, Mawuenyega KG, Wen G, Browning KR, Sigurdson WC, Yarasheski KE, Friedrich SW, Demattos RB, May PC, Paul SM, Holtzman DM. (2009)
A gamma-secretase inhibitor decreases amyloid-beta production in the central nervous system. Ann Neurol. Mar 18. [Epub ahead of print] PMID: 19360898
Fagan AM, Head D, Shah AR, Marcus D, Mintun M, Morris JC, Holtzman DM. (2009) Decreased cerebrospinal fluid Abeta(42) correlates with brain atrophy in cognitively normal elderly. Ann Neurol. Feb;65(2):176-83.
West T, Stump S, Lodygensky G, Neil JJ, Deshmukh M Holtzman DM. (2009) Lack of X-linked inhibitor of apoptosis protein leads to increased apoptosis and tissue loss following neonatal hypoxic-ischemic brain injury. ASN Neuro. Mar6; online
Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, Holtzman DM. (2009) Amyloid- β Dynamics Are Regulated by Orexin and the Sleep-Wake Cycle. Science. DOI: 10.1126/science.1180962
(Download the pdf of this paper here)
|
